Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions
Primary Purpose
Fed
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Desloratadine
Sponsored by
About this trial
This is an interventional treatment trial for Fed
Eligibility Criteria
Inclusion Criteria:
- Is the individual a healthy, normal adult man and women who volunteers to participate?
- Is s/he within 18 and 45 years of age, inclusive?
- Is his/her BMI between 19 and 30, inclusive?
- Is she willing to avoid pregnancy by abstaining from sexual intercourse with a non-sterile male partner, or by the use one of the following methods: diaphragm + spermicide or condom + spermicide (at least 14 days before dosing), intra-uterine contraceptive device or hormonal contraceptives (at least 4 weeks prior to dosing), or has she been surgically sterile or post-menopausal at least six months prior to entering into the study?
- Is s/he considered reliable and capable of understanding his/her responsibility and role in the study?
- Has s/he provided written informed consent?
A no answer to any of the above questions indicates that the individual is ineligible for enrollment
Exclusion Criteria:
Does the individual have a history of allergy or hypersensitivity to desloratadine?
- Does s/he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
- Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
- Is she nursing?
- Does s/he have serious psychological illness?
- Does s/he have significant history (within the past year) or clinical evidence of alcohol or drug abuse?
- Does s/he have a positive urine drug screen or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test?
- Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken in each study period? .
- Has s/he used any prescription drug, other than hormonal contraceptives, during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation?
- Is s/he unable to refrain from the use of all concomitant medications, other than hormonal contraceptives, during the study?
- Has s/he donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation?
- Has s/he donated plasma during the two week period preceding study initiation?
- Has s/he used any tobacco products in the 3 months preceding drug administration?
- Has s/he received an investigational drug during the 30 day period preceding study initiation? A yes answer to any of the above questions indicates that the individual is ineligible for enrollment.
Sites / Locations
- SFBC, Ft. Myers, Inc.,
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Desloratadine Tablets, 5 mg
Clarinex
Arm Description
Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
Clarinex® 5 mg Tablets of Schering-Plough
Outcomes
Primary Outcome Measures
Bioavailability is based on Cmax and AUC parameters
Secondary Outcome Measures
Full Information
NCT ID
NCT01314352
First Posted
March 11, 2011
Last Updated
June 7, 2011
Sponsor
Dr. Reddy's Laboratories Limited
1. Study Identification
Unique Protocol Identification Number
NCT01314352
Brief Title
Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions
Official Title
A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Healthy Subjects Under Fed Conditions
Study Type
Interventional
2. Study Status
Record Verification Date
June 2011
Overall Recruitment Status
Completed
Study Start Date
December 2005 (undefined)
Primary Completion Date
December 2005 (Actual)
Study Completion Date
March 2006 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Dr. Reddy's Laboratories Limited
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to compare the rate and extent of absorption of Dr. Reddy's Desloratadine 5 mg tablet to that of Clarinex® 5 mg tablet in healthy subjects under fed conditions.
Detailed Description
A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in fed Normal,Healthy subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fed
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
28 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Desloratadine Tablets, 5 mg
Arm Type
Experimental
Arm Description
Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
Arm Title
Clarinex
Arm Type
Active Comparator
Arm Description
Clarinex® 5 mg Tablets of Schering-Plough
Intervention Type
Drug
Intervention Name(s)
Desloratadine
Other Intervention Name(s)
Clarinex® 5 mg
Intervention Description
Desloratadine Tablets, 5 mg
Primary Outcome Measure Information:
Title
Bioavailability is based on Cmax and AUC parameters
Time Frame
4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Is the individual a healthy, normal adult man and women who volunteers to participate?
Is s/he within 18 and 45 years of age, inclusive?
Is his/her BMI between 19 and 30, inclusive?
Is she willing to avoid pregnancy by abstaining from sexual intercourse with a non-sterile male partner, or by the use one of the following methods: diaphragm + spermicide or condom + spermicide (at least 14 days before dosing), intra-uterine contraceptive device or hormonal contraceptives (at least 4 weeks prior to dosing), or has she been surgically sterile or post-menopausal at least six months prior to entering into the study?
Is s/he considered reliable and capable of understanding his/her responsibility and role in the study?
Has s/he provided written informed consent?
A no answer to any of the above questions indicates that the individual is ineligible for enrollment
Exclusion Criteria:
Does the individual have a history of allergy or hypersensitivity to desloratadine?
Does s/he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
Is she nursing?
Does s/he have serious psychological illness?
Does s/he have significant history (within the past year) or clinical evidence of alcohol or drug abuse?
Does s/he have a positive urine drug screen or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test?
Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken in each study period? .
Has s/he used any prescription drug, other than hormonal contraceptives, during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation?
Is s/he unable to refrain from the use of all concomitant medications, other than hormonal contraceptives, during the study?
Has s/he donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation?
Has s/he donated plasma during the two week period preceding study initiation?
Has s/he used any tobacco products in the 3 months preceding drug administration?
Has s/he received an investigational drug during the 30 day period preceding study initiation? A yes answer to any of the above questions indicates that the individual is ineligible for enrollment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antonio R. Pizarro, M.D.,
Organizational Affiliation
SFBC Ft. Myers, Inc
Official's Role
Principal Investigator
Facility Information:
Facility Name
SFBC, Ft. Myers, Inc.,
City
Ft. Myers
State/Province
Florida
ZIP/Postal Code
33901
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions
We'll reach out to this number within 24 hrs